2020 On-site Forms Industry and Scientific Advisory Board
2020 On-site has formed an Industry and Scientific Advisory Board (IASAB) that will steer its initiatives by gathering insights, sharing ideas, and debating critical business concepts.
The board’s seven members will gather quarterly to identify patient needs, product opportunities and market challenges associated with the provision of vision-related assessments for clinical trials and safety surveillance programs.
On the board are Ms. Jeanne Taylor Hecht, IASAB chair and the founder and CEO of JTH Consulting, LLC; Rajat Agrawal MD, MS, CEO and president of Retina Global; Jeffrey S. Heier, MD, director of the vitreoretinal service and retina research at Ophthalmic Consultants of Boston; Peter K. Kaiser, MD, Chaney Family Endowed Chair in Ophthalmology Research and a professor of ophthalmology at the Cleveland Clinic Lerner College of Medicine; Beth Marsh, vice president of North America Sales and Marketing, Ophthalmology, for Apellis Pharmaceuticals; Jason Menzo, Chief Operating Officer of Foundation Fighting Blindness; and Adam Ramsey, OD, an optometrist and owner of Socialite Vision.
For more information, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
